Abstracts tagged "informatics"

Abstract Number: 1302 • ACR Convergence 2020
Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations
April Jorge¹, Zhiyao Wu², Tashrif Chowdhury² and Yijun Zhao², ¹Massachusetts General Hospital, Boston, MA, ²Fordham University, Computer and Information Sciences Department, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease associated with increased morbidity and mortality, and severe SLE flares can lead to hospitalizations. Our objective…
Abstract Number: 1545 • ACR Convergence 2020
An Artificial Intelligence (AI) Assistant Identifying Spinal Diffuse Idiopathic Skeletal Hyperostosis on Plain X-rays: A Pilot Deep Learning Study
Sarah Ringsted¹, Nishad Sathe¹, Atul Deodhar² and Dongseok Choi², ¹Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR
Background/Purpose: Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory condition most classically seen in the spine, and is characterized by ossification of the spinal ligaments…
Abstract Number: 1597 • ACR Convergence 2020
Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy
Taylor Nelson¹, Gary Kunkel² and Grant Cannon², ¹University of Utah, Salt Lake City, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City
Background/Purpose: Rheumatoid Arthritis (RA) management guidelines recommend the collection of Disease Activity Measures (DAMs) to direct therapy as a component of a “treat-to-target” (T2T) strategy. …
Abstract Number: 1745 • ACR Convergence 2020
A Novel Method for Predicting 1-Year Retention of Abatacept Using Machine Learning Techniques
Rieke Alten¹, Claire Behar², Christine Boileau², Pierre Merckaert², Ebenezer Afari², Virginie Vannier-Moreau³, Sean Connolly³, Yedid Elbez², Pierre-Antoine Juge⁴ and Karissa Lozenski³, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Excelya, Boulogne-Billancourt, France, ³Bristol-Myers Squibb Company, Princeton, NJ, ⁴Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France
Background/Purpose: In the ACTION (NCT02109666) study, using multivariable Cox proportional hazards regression models, patient (pt) global assessment of pain, country, reason for stopping last biologic,…
Abstract Number: 1788 • ACR Convergence 2020
Assessment of the Impact of Interferon Levels on Cognitive Dysfunction in Patients with SLE
Andrew Kwan¹, Joan Wither², Juan Pablo Diaz-Martinez², Robin Green³, Dorcas Beaton⁴, Mahta Kakvan², Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su², Dennisse Bonilla², Nicole Anderson², Patricia Katz⁸ and Zahi Touma⁹, ¹University of Toronto, Department of Medicine, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University of California, San Francisco, Novato, CA, ⁹University of Toronto, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is among the earliest and the most prevalent manifestations of SLE. Previous studies have demonstrated that the increased levels of interferon…
Abstract Number: 2888 • 2019 ACR/ARP Annual Meeting
Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions
Francine Castillo¹, Adrienne Strait ², Michael Evans ³, Julia Kay ⁴, Milena Gianfrancesco ⁵, Zara Izadi ⁶, Laura Trupin ¹, Mylien Hoang ⁷, James Shalaby ⁸, Gabriela Schmajuk ⁹ and Jinoos Yazdany ⁴, ¹University of California, San Francisco, San Francisco, CA, ²UCSF School of Medicine, San Francisco, CA, ³University of California San Francisco, San Francisco, ⁴UCSF Division of Rheumatology, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, ⁶UCSF Division of Rheumatology, San Francisco, ⁷Touro University, San Francisco, ⁸Elimu Informatics, San Francisco, ⁹UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: Prednisone is commonly used to treat rheumatic diseases, yet few comparative effectiveness studies on different dosing regimens are available. Electronic health records (EHR) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.